Tarsus annual meeting: directors elected, say-on-pay approved, Ernst & Young ratified

Tarsus Pharmaceuticals, Inc.

Stockholders elected Bobak Azamian, M.D., Ph.D. (20.8M for) and Katherine Goodrich, M.D. (26.8M for) as Class II directors.
Non-binding advisory vote approved named executive officer compensation: 27.1M for, 416,845 against, 16,635 abstain.
Stockholders selected an every-1-year frequency for future say-on-pay votes (26.9M votes for 1 year).
Ratification of Ernst & Young LLP as independent auditor for FY2025 approved: 34.7M for, 125,755 against, 7,803 abstain.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.